NNC9204-0530 and Liraglutide Combination Safety, PK Explored in Overweight Males
Investigate Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-0530 Alone and in Combination With Liraglutide in Overweight to Obese But Otherwise Healthy Male Subjects
Background
Obesity is a chronic disease with significant health implications, often requiring pharmacological intervention. While existing treatments like liraglutide (a GLP-1 receptor agonist) are effective, there's a continuous need for novel compounds and combination therapies to improve efficacy, reduce side effects, and expand treatment options. Investigating new agents like NNC9204-0530 and its synergy with established therapies aims to address unmet needs in weight management by exploring initial safety and drug-drug interactions.